CMRI Granted US Patent for Kidney Disease Therapy
Children’s Medical Research Institute and Massachusetts General Hospital in Boston, Massachusetts, USA, have been granted an issued patent in the United States for a novel method of treating chronic kidney disease. The same patent is pending in other major jurisdictions including Europe, China, Japan, Brazil and Australia.
Professor Phil Robinson, Head of the Cell Signalling Group at CMRI, together with collaborators at Massachusetts General Hospital, originally discovered the concept that drugs, called “Ring Stabilizers”, interact with and promote the activation of an enzyme named dynamin. The scientists have now generated data that indicates that these drugs have the potential to treat or prevent kidney disease or conditions characterised by proteinuria, an important biomarker of kidney dysfunction.
The global epidemic of chronic kidney disease is progressing at an alarming rate, with up to 11% of the general population affected in the US, Australia, Japan and Europe. Current therapies have limited efficacy and significant side effects, with long term patients often deteriorating to a stage where they require dialysis or kidney transplant.
The Cell Signalling Group has a long standing collaboration and partnership with the laboratory of Professor Adam McCluskey at the Department of Chemistry, University of Newcastle, to design and develop Ring Stabilizer drugs. Granting of this new US Patent (8,809,386) provides a foundation on which this collaboration can develop and ultimately commercialise these innovative drugs as a new therapy option for kidney disease patients.